1. Quality Control Indicators for Transurethral Resection of Non–Muscle-Invasive Bladder Cancer
   Murat Akand et al, 2019, Clinical Genitourinary Cancer CrossRef
2. Comparative study between mitomycin C versus Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer
   Mohamed Mahmoud Abdelfatah Zaza et al, 2024, Urologia Journal CrossRef
3. PC4 promotes bladder cancer progression and stemness by directly interacting with Sp1 to transcriptionally activate the Wnt5a/β-catenin pathway
   Benhuang Yan et al, 2024, Pathology - Research and Practice CrossRef
4. Proteomic analysis of the urothelial cancer landscape
   Franz F. Dressler et al, 2024, Nature Communications CrossRef
5. Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette‐Guérin (BCG) treatment
   Pertti Nurminen et al, 2019, BJU International CrossRef
6. Encapsulation of hydroxycamptothecin within porous and hollow poly(l-lactide-co-ε-caprolactone) microspheres as a floating delivery system for intravesical instillation
   Shiya Zhuang et al, 2024, Biomaterials Science CrossRef
7. Non–muscle‐invasive bladder cancer: Intravesical treatments beyond Bacille Calmette‐Guérin
   Vignesh T. Packiam et al, 2017, Cancer CrossRef
8. Benzyl isothiocyanate suppresses IGF1R, FGFR3 and mTOR expression by upregulation of miR-99a-5p in human bladder cancer cells
   Ji-Fan Lin et al, 2019, International Journal of Oncology CrossRef
9. Recurrent Sigmoid Diverticulitis After Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for Bladder Cancer
   Ayesha Kamal et al, 2021, SN Comprehensive Clinical Medicine CrossRef
10. Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway
    Kehua Jiang et al, 2017, Oncology Letters CrossRef
11. A pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: An application for bladder cancer treatment
    Marian Vila-Caballer et al, 2016, Journal of Controlled Release CrossRef
12. Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
    Zongren Wang et al, 2018, BMC Cancer CrossRef